Drug Profile
Research programme: anti-infective vaccines - TVAX Biomedical
Alternative Names: TVI-Hepatitis-1; TVI-HIV-1; TVI-Tuberculosis-1Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator TVAX Biomedical
- Class AIDS vaccines; Antituberculars; Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis; HIV infections; Tuberculosis
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Hepatitis in USA (IV)
- 28 Apr 2022 No recent reports of development identified for preclinical development in HIV-infections in USA (IV)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Tuberculosis in USA (IV)